Page last updated: 2024-09-04

evodiamine and Leukemia

evodiamine has been researched along with Leukemia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dong, F; Liu, X; Luan, C; Luan, S; Shao, H; Sun, C; Zhang, G1
Bligh, SW; Hartley, JA; Hartley, JM; Pan, X; Wang, Z; White, KN1

Other Studies

2 other study(ies) available for evodiamine and Leukemia

ArticleYear
Evodiamine inhibits the proliferation of leukemia cell line K562 by regulating peroxisome proliferators-activated receptor gamma (PPARγ) pathway.
    Journal of receptor and signal transduction research, 2016, Volume: 36, Issue:4

    Topics: Anilides; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia; PPAR gamma; Quinazolines

2016
Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2012, May-15, Volume: 19, Issue:7

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Evodia; Fruit; Humans; Inhibitory Concentration 50; Leukemia; Phytotherapy; Quinazolines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors

2012
chemdatabank.com